Artiva Biotherapeutics (NASDAQ:ARTV) SVP Heather Raymon Sells 3,095 Shares

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) SVP Heather Raymon sold 3,095 shares of the business’s stock in a transaction dated Tuesday, May 19th. The shares were sold at an average price of $9.01, for a total value of $27,885.95. Following the completion of the sale, the senior vice president directly owned 148,228 shares of the company’s stock, valued at $1,335,534.28. The trade was a 2.05% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Artiva Biotherapeutics Price Performance

Shares of Artiva Biotherapeutics stock opened at $7.84 on Thursday. The business has a 50-day simple moving average of $8.36 and a 200 day simple moving average of $5.67. The firm has a market capitalization of $193.80 million, a price-to-earnings ratio of -2.21 and a beta of 2.86. Artiva Biotherapeutics, Inc. has a one year low of $1.47 and a one year high of $14.53.

Artiva Biotherapeutics (NASDAQ:ARTV) last announced its quarterly earnings data on Friday, May 8th. The company reported ($0.95) EPS for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.07). On average, sell-side analysts expect that Artiva Biotherapeutics, Inc. will post -2.45 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have recently weighed in on ARTV. HC Wainwright raised their target price on Artiva Biotherapeutics from $15.00 to $35.00 and gave the company a “buy” rating in a report on Friday, May 8th. Wall Street Zen lowered Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a report on Sunday. Weiss Ratings restated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a report on Friday, April 24th. Needham & Company LLC raised their target price on Artiva Biotherapeutics from $18.00 to $41.00 and gave the company a “buy” rating in a report on Tuesday, May 12th. Finally, Wedbush raised their target price on Artiva Biotherapeutics from $23.00 to $40.00 and gave the company an “outperform” rating in a report on Monday, May 11th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $39.00.

Institutional Trading of Artiva Biotherapeutics

A number of hedge funds have recently bought and sold shares of ARTV. Citadel Advisors LLC raised its stake in shares of Artiva Biotherapeutics by 419.3% in the third quarter. Citadel Advisors LLC now owns 798,397 shares of the company’s stock valued at $2,291,000 after buying an additional 644,658 shares during the period. BNP Paribas Financial Markets raised its stake in shares of Artiva Biotherapeutics by 14,463.5% in the third quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company’s stock valued at $340,000 after buying an additional 117,733 shares during the period. Marshall Wace LLP bought a new stake in shares of Artiva Biotherapeutics in the fourth quarter valued at $341,000. Jane Street Group LLC bought a new stake in shares of Artiva Biotherapeutics in the second quarter valued at $67,000. Finally, Landscape Capital Management L.L.C. bought a new stake in shares of Artiva Biotherapeutics in the third quarter valued at $112,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.